The synergy between the cutting-edge features of the MCT Kit^® and the versatile functionality of the MCT Unit^® forms the foundation of a revolutionary innovation conceived to elevate the regenerative potential of PRP and cell-based therapies, while stimulating the production and deliverance of autologous exosomes.

The MCT Unit^® emits light across a versatile wavelength spectrum (467 nm to 850 nm): blue light (467 nm), green light (530 nm), yellow light (591 nm), red light (620 nm), and infrared light (850 nm). Additionally, it is equipped to stimulate biological materials within a temperature range of 4ºC to 45ºC.

The MCT Kit^® is a patented medical-grade cassette serving as the receptacle for patient material, uniquely crafted to fit in the MCT Unit^®. It has two syringe docking sites (standard and Luer Lock^® compatible) to insert and extract autologous material.

Direct exposure of cells to light profoundly affects chromophores, including cytochrome C oxidase and opsins. These light-responsive receptors activate second messengers (ROS, Ca²⁺, ATP, cAMP, NO), modulating cell signaling pathways.

It is well known that low temperatures (4ºC) prime platelet activation and trigger the release of growth factors (VEGF, EGF, and bFGF) from α-granules. Additionally, temperature directly influences exosome secretion kinetics, with increased exosome release at higher temperatures (37ºC).

All autologous materials can be enhanced with the MCT System. That is, basically, PRP, SVF, and every other regenerative medicine preparate. Therapy enhancement translates, for instance, into considerably fewer sessions and stunning clinical results. Safe, effective, evidence-proof photothermal boosting treatments are here to stay.

There is a “flash” effect that can be seen almost immediately and an antiaging effect whose results can be seen in less than a month but can be enhanced with time due to the regenerative power of exosomes.

PRP preset is recommended for plasma-derived products, such as PRP (platelet-rich plasma) or PPP (platelet-poor plasma). Cells preset is versatile and can be used with: biopsies, stromal vascular fraction, stem cells, as well as other cell types. Exosomes preset is suitable for any autologous liquid containing living cells or platelets.

For MCT Technology to exert its therapeutic effects, autologous material must be liquid and contain living cells or platelets.

The MCT protocol involves 3 key steps. First, procuring the autologous material from the patient. Second, inserting the patient’s material into the MCT Kit^®. Third, setting up the MCT Unit^® with the loaded MCT Kit^®, running the preferred MCT preset, extracting the MCT material once the session is over, and administering it to the patient.

Yes. There are 3 different MCT presets (PRP, Cells, and Exosomes) which can be combined or used individually according to physician criteria.

A combined MCT treatment merges PRP or Cells presets with the Exosomes preset for enhanced therapeutic results. Split any autologous sample in two halves. Use the first one with either PRP or Cells presets and the second with the exosomes preset.

The MCT Kit^® allows a maximum of 10 mL. While 10 mL is enough for individual MCT treatments, a higher volume will generally be needed for combined treatments.

Single preset treatments require 10 to 15 minutes. Combined preset treatments require 25 minutes.

Many physicians recommend a scheme of 3 sessions with a 3-week interval and maintaining a span of 4-6 months between subsequent maintenance sessions. While this timeline serves as a general guideline, every physician will tailor the procedure to the specific needs.

Exosomes originating from keratinocytes, fibroblasts, stem cells, and diverse skin cells play a pivotal role in a range of critical functions, spanning from the self-renewal of the epidermis to skin regeneration, hair follicle stem cell proliferation and differentiation, and the modulation of immunological processes crucial for skin homeostasis.

Exosomes, with their unique ability to transfer biological information and promote tissue repair, emerge as a promising strategy for addressing diverse skin disorders. From wound healing to pigmentation regulation, skin rejuvenation, hair loss recovery, and scar remodeling, exosomes hold promise in diverse therapeutic applications.

The main distinctive factor among autologous, allogeneic, and xenogeneic exosomes lies in their source. Autologous exosomes originate from cells of the same individual, allogeneic exosomes derive from cells of a different individual of the same species, and xenogeneic exosomes come from cells of a different species.

Autologous exosomes benefit from immune privilege, while heterologous exosomes are prone to triggering an immune response in the patient. The resulting immunogenic response contributes to the short-lived nature of heterologous exosomes, limiting their efficacy and therapeutic potential. Safety concerns also arise from the potential risk of cross- or intra-species contamination associated with the use of heterologous exosomes. All these factors position autologous exosomes as a valid medicinal therapeutic option, while heterologous exosomes are primarily confined to cosmetic applications.

Unlike conventional methods that merely isolate or concentrate exosomes in cosmetic products, our technology goes beyond; it actively stimulates the release of naïve exosomes from cells and platelets. This unique approach sets MCT technology apart from other products in the market, positioning us as the only secure, efficient, potent, and reliable therapeutic option.

MCT technology elevates standard PRP, enhancing growth factor release, refining platelet activation, reducing proinflammatory cytokines, optimizing pH balance, decreasing plasma density for a more comfortable injection, and stimulating platelet metabolism via ATP synthesis.